TY - JOUR
T1 - Protective role of chaperone-mediated autophagy against atherosclerosis
AU - Madrigal-Matute, Julio
AU - de Bruijn, Jenny
AU - van Kuijk, Kim
AU - Riascos-Bernal, Dario F
AU - Diaz, Antonio
AU - Tasset, Inmaculada
AU - Martín-Segura, Adrián
AU - J.J. Gijbel, Marion
AU - Sander, Bianca
AU - Kaushik, Susmita
AU - Biessen, Erik A.L.
AU - Tiano, Simoni
AU - Bourdenx, Mathieu
AU - J. Krause, Gregory
AU - McCracken, Ian
AU - Baker, Andrew H
AU - Han, Jin
AU - Sibinga, Nicholas
AU - Bravo-Cordero, Jose Javier
AU - Macian, Fernando
AU - Singh, Rajat
AU - Rensen, Patrick C.N.
AU - Berbée, Jimmy F.P.
AU - Pasterkamp, Gerard
AU - Sluimer, Judith
AU - Cuervo, Ana Maria
N1 - Funding Information:
We thank Trea Streefland (Leiden University Medical Center) for her assistance with generating the lipid profiles, and Jacques Debets and Clairy Dinjens (Maastricht University Medical Center) for assistance with sectioning and immunohistochemistry. The GTEx Project used for the calculation of CMA scores was supported by the Common Fund of the Office of the Director of the NIH, and the Tabula Sapiens Project, used for the same purpose, was supported by Grant 2019-203354 from the Chan Zuckerberg Initiative DAF. This work was supported by NIH Grants AG021904 and DK098408 (to A.M.C.) and AG031782 (to A.M.C., R.S., J.J.B.-C., and F.M.), the Leducq Foundation Network (A15CVD04 to A.M.C. and J.C.S.), and a Dr. Dekker Senior Postdoc Fellowship from the Dutch Heart Foundation (2016T060 to J.C.S.). J.M.-M. was supported by a postdoctoral fellowship from the American Heart Association (17POST33650088), A.M.-S. by a Ramon Areces Postdoctoral Fellowship, and G.J.K. by TGT32GM007288 and T32GM007491.
Funding Information:
ACKNOWLEDGMENTS. We thank Trea Streefland (Leiden University Medical Center) for her assistance with generating the lipid profiles, and Jacques Debets and Clairy Dinjens (Maastricht University Medical Center) for assistance with sectioning and immunohistochemistry. The GTEx Project used for the calculation of CMA scores was supported by the Common Fund of the Office of the Director of the NIH, and the Tabula Sapiens Project, used for the same purpose, was supported by Grant 2019-203354 from the Chan Zuckerberg Initiative DAF. This work was supported by NIH Grants AG021904 and DK098408 (to A.M.C.) and AG031782 (to A.M.C., R.S., J.J.B.-C., and F.M.), the Leducq Foundation Network (A15CVD04 to A.M.C. and J.C.S.), and a Dr. Dekker Senior Postdoc Fellowship from the Dutch Heart Foundation (2016T060 to J.C.S.). J.M.-M. was supported by a postdoctoral fellowship from the American Heart Association (17POST33650088), A.M.-S. by a Ramon Areces Postdoctoral Fellowship, and G.J.K. by TGT32GM007288 and T32GM007491.
Publisher Copyright:
Copyright © 2022 the Author(s).
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Chaperone-mediated autophagy (CMA) contributes to regulation of energy homeostasis by timely degradation of enzymes involved in glucose and lipid metabolism. Here, we report reduced CMA activity in vascular smooth muscle cells and macrophages in murine and human arteries in response to atherosclerotic challenges. We show that in vivo genetic blockage of CMA worsensatherosclerotic pathology through both systemic and cell-autonomous changes in vascular smooth muscle cells and macrophages, the two main cell types involved in atherogenesis. CMA deficiency promotes dedifferentiation of vascular smooth muscle cells and a pro-inflammatory state in macrophages. Conversely, a genetic mouse model with upregulated CMA shows lower vulnerability to the pro-atherosclerotic challenge. We propose that CMA could be an attractive therapeutic target against cardiovascular diseases.
AB - Chaperone-mediated autophagy (CMA) contributes to regulation of energy homeostasis by timely degradation of enzymes involved in glucose and lipid metabolism. Here, we report reduced CMA activity in vascular smooth muscle cells and macrophages in murine and human arteries in response to atherosclerotic challenges. We show that in vivo genetic blockage of CMA worsensatherosclerotic pathology through both systemic and cell-autonomous changes in vascular smooth muscle cells and macrophages, the two main cell types involved in atherogenesis. CMA deficiency promotes dedifferentiation of vascular smooth muscle cells and a pro-inflammatory state in macrophages. Conversely, a genetic mouse model with upregulated CMA shows lower vulnerability to the pro-atherosclerotic challenge. We propose that CMA could be an attractive therapeutic target against cardiovascular diseases.
U2 - 10.1073/pnas.2121133119
DO - 10.1073/pnas.2121133119
M3 - Article
SN - 0027-8424
JO - Proceedings of the National Academy of Sciences (PNAS)
JF - Proceedings of the National Academy of Sciences (PNAS)
ER -